CAS: 13665-88-8; Mopidamol

该化合物是一种化学化合物,主要用于医疗用途,特别是治疗边缘血管疾病,被归类为血管病,这意味着它通过放松血管血管来改善血液流动;甲型甲型甲型六氯环己烷的分子结构包括一个管状腺,有助于其药理特性;众所周知,它具有抗塑剂和抗血栓效应,有利于预防血凝块;该化合物通常以口服形式施用,并研究其对改善循环和减少与缺血病有关的症状的潜在影响;在安全和毒性方面,它与许多药物一样,应该由医疗监督使用,因为它可能具有副作用或与其他药物相互作用;

结构式图片

MSDS等安全信息

    合成工艺路线路线简述

      📜2-甲巯基-5-氨基嘧啶-4-羧酸置于五氯化磷,N,N-二异丙基乙胺,间氯过氧苯甲酸,N,N'-羰基二咪唑,三氯氧磷体系中,用 四氢呋喃 用作溶剂,化学反应 24.5H,反应生成蒙匹胺醇
      参考文献:莫哌达醇的合成方法
      标题:莫哌达醇的合成方法
      摘要:本申请公开了莫哌达醇,即2,2,2,2‑(4‑(哌啶‑1‑基)嘧啶并[5,4‑d]嘧啶‑2,6‑二基)双(氮杂三基)四(乙基‑1‑醇)的制备方法,该制备方法收率非常好,产物纯度高,反应条件温和,成本低.

      海关参考信息

      专利信息


      专利号:US-12391691-B2
      优先权日:2018-11-16
      标题:Synthesis of key intermediate of KRAS G12C inhibitor compound
      发明人:PARSONS ANDREW THOMAS; COCHRAN BRIAN MCNEIL; POWAZINIK IV WILLIAM; CAPORINI MARC ANTHONY
      权利人:AMGEN INC
      摘要:The present invention relates to an improved, efficient, scalable process to prepare intermediate compounds, such as compound 5M, having the structure n nuseful for the synthesis of compounds that target KRAS G12C mutations, such as

      专利号:US-2025206736-A1
      优先权日:2019-11-14
      标题 :Synthesis of kras g12c inhibitor compound
      发明人:CORBETT MICHAEL THOMAS; CAILLE SEBASTIEN
      权利人:AMGEN INC
      摘要:The present disclosure relates to an improved, efficient, scalable process to prepare intermediate compounds, such as 2-isopropyl-4-methylpyridin-3-amine, useful for the synthesis of compounds, such as Compound 9, for the treatment of KRAS G12C mutated cancers.

      专利号:US-9315483-B2
      优先权日:2007-09-13
      标题 :Synthesis of deuterated catechols and benzo[D][1,3]dioxoles and derivatives thereof
      发明人:JONES ANDREW D; ZELLE ROBERT E; SILVERMAN I ROBERT
      权利人:CONCERT PHARMACEUTICALS INC
      摘要:The present invention provides a convenient and efficient process for the synthesis of d 2 -benzo[d][1,3]dioxoles.

      专利号:US-2022233673-A1
      优先权日:2019-06-04
      标 题:METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STxB) MONOMERS AND OLIGOMERS, AND USES THEREOF
      发明人:BILLET ANNE; SCHMIDT FRÉDÉRIC; JOHANNES LUDGER; SERVENT DENIS; MOURIER GILLES; TARTOUR ÉRIC; KAY MICHAEL; FULCHER JAMES M
      权利人:INST CURIE; CENTRE NAT RECH SCIENT; INST NAT SANTE RECH MED; COMMISSARIAT A LENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES CEA; APHP ASSIST PUBLIQUE HOPITAUX DE PARIS; UNIV PARIS; UNIV OF UTAH RESEARCH FOUDATION; UNIV UTAH RES FOUND
      摘要:A method of producing a monomer of a Shiga toxin B-subunit (STxB) protein or of a variant thereof by peptide chemical synthesis, as well as to a method of producing a pentamer of the STxB protein or of the variant thereof. The methods are particularly advantageous as they overcome major issues typically observed in peptide chemical synthesis, including solubility and purity issues.

      专利号:US-8734846-B2
      优先权日:2008-06-16
      标 题 :Methods for the preparation of targeting agent functionalized diblock copolymers for use in fabrication of therapeutic targeted nanoparticles
      发明人:ALI MIR M; HRKACH JEFF; ZALE STEPHEN E; ALVAREZ DE CIENFUEGOS LUIS
      权利人:BIND BIOSCIENCES INC
      摘要:This application provides nanoparticles and methods of making nanoparticles using pre-functionalized poly(ethylene glycol)(also referred to as PEG) as a macroinitiator for the synthesis of diblock copolymers. Ring opening polymerization yields the desired poly(ester)-poly (ethylene glycol)-targeting agent polymer that is used to impart targeting capability to therapeutic nanoparticles. This “polymerization fromâ€? approach typically employs precursors of the targeting agent wherein the reactivity of functional groups of the targeting agent is masked using protecting groups. Also described is a “coupling toâ€? that utilized the poly(ethylene glycol)-targeting agent conjugate where the targeting agent remains in its native un-protected form. This method uses “orthogonalâ€? chemistry that exhibit no cross reactivity towards functional groups typically found within targeting agents of interest.

      专利号:US-2013035307-A1
      优先权日:2010-01-26
      标 题:Methods for treating or preventing the spread of cancer using semi-synthetic glycosaminoglycosan ethers
      发明人:PRESTWICH GLENN D; KENNEDY THOMAS P
      权利人:UNIV UTAH RES FOUND; PRESTWICH GLENN D; KENNEDY THOMAS P
      摘要:Described herein are methods for the treatment and prevention of tumor metastasis using alkylated and fluoroalkylated semi-synthetic glycosaminoglycan ethers (“SAGEsâ€?). The synthesis of sulfated alkylated and fluoroalkylated SAGEs is also described.

      供应商参考报价(招募中)

      品牌试剂参考报价(招募中)

      📌 第三方产品分析报告

      ✅ COA系统入驻 | 共享模式

      主要参考文献


      1: Blaha H, Dierkesmann R, Feuerer W, Gatzemaier U, Geser C, Lemme J, Mall W, Ritscher R, Schneider B, Vallee D. [Adjuvant therapy of non-small cell bronchial cancer with mopidamol]. Pneumologie. 1989 Jun;43(6):299-304. German. Review. German. Review. Review.

      合成参考文献


      摘要:German Offenlegungsschrift Patent Document., #2931573
      摘要:Ambrus JL, Stadler I, Kulaylat M, Koreshi A, Akhtar S. Hemorrheologic effects of pyrimido-pyrimidine derivatives. J Med. 1996;27(1-2):21–32.
      参考文献:10.1007/bf02536177
      摘要:de la Cruz JP, Carrasco T, Ortega G, Sanchez de la Cuesta F. Inhibition of ferrous-induced lipid peroxidation by pyrimido-pyrimidine derivatives in human liver membranes. Lipids. 1992 Mar;27(3):192–4. doi: 10.1007/bf02536177.
      参考文献:10.1016/0305-7372(85)90006-4
      摘要:Lichtner RB, Hutchinson G, Wedderburn N, Hellmann K. Antiplatelet pyrimido-pyrimidines and metastasis. Cancer Treat Rev. 1985 Dec;12(4):221–34. doi: 10.1016/0305-7372(85)90006-4.
      参考文献:10.1016/0049-3848(86)90057-5
      摘要:Dawicki DD, Agarwal KC, Parks RE. Potentiation of the antiplatelet action of adenosine in whole blood by dipyridamole or dilazep and the cAMP phosphodiesterase inhibitor, RA 233. Thromb Res. 1986 Jul 15;43(2):161–75. doi: 10.1016/0049-3848(86)90057-5.
      📝 需求与反馈
      尽可能描述清楚需求与问题信息
      ×

      通知